Osmotic Nifedipine Dosage Form with Immediate Release Jacket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical dosage forms for hypertension treatment often require frequent administration and can cause peak-trough plasma concentration fluctuations, leading to side effects, and existing formulations fail to provide a stable combination of nifedipine or nisoldipine with angiotensin II antagonists and diuretics that achieve optimal blood pressure control and bioequivalence.
Innovation Solution
A pharmaceutical dosage form featuring an osmotic release system with nifedipine or nisoldipine in the core and an angiotensin II antagonist and/or diuretic in a jacket coating, using partially hydrolyzed polyvinyl alcohol as a film-forming polymer, ensuring rapid release of the antagonist and controlled release of nifedipine, thereby achieving once-daily administration and stable bioequivalence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If nifedipine or nisoldipine is administered rapidly to achieve quick blood pressure reduction, then the onset of action is improved, but peak-trough plasma concentration fluctuations increase causing side effects
Solution Approach 1:
The patent applies dynamic release principles by using an osmotic pump system that adjusts drug release rate in response to physiological conditions. The system maintains a constant release rate of nifedipine/nisoldipine over 24 hours, eliminating peak-trough fluctuations while ensuring rapid initial action through the angiotensin II antagonist/co-diuretic coating layer.
Solution Approach 2:
The patent implements preliminary action by incorporating an angiotensin II antagonist and/or co-diuretic in the outer coating layer that releases immediately upon administration. This provides rapid initial blood pressure control before the sustained-release calcium channel blocker takes full effect, preventing the need for high initial doses that cause fluctuations.
2Ease of operation
If monotherapy with a single antihypertensive drug is used to simplify treatment, then ease of operation is improved, but blood pressure control effectiveness deteriorates
Solution Approach 1:
The patent merges three different antihypertensive mechanisms into a single tablet formulation: angiotensin II antagonist, co-diuretic, and calcium channel blocker (nifedipine/nisoldipine). This combination therapy provides comprehensive blood pressure control while maintaining once-daily administration simplicity, addressing both effectiveness and ease of operation.
Solution Approach 2:
The single tablet formulation serves multiple functions simultaneously: the angiotensin II antagonist component addresses renal protection, the co-diuretic component manages fluid balance, and the calcium channel blocker provides vasodilation. This multi-functional approach replaces multiple separate medications while maintaining therapeutic effectiveness.
3Reliability
If frequent administration is required to maintain stable plasma levels, then blood pressure control effectiveness is improved, but loss of time and patient compliance deteriorate
Solution Approach 1:
The patent ensures continuous useful action through the 24-hour sustained-release osmotic pump system that maintains constant plasma levels of nifedipine/nisoldipine. This continuous release mechanism eliminates the need for multiple daily administrations while maintaining effective blood pressure control, reducing both time loss and improving patient compliance.
4Ease of operation
If a combination formulation is developed to reduce administration frequency, then ease of operation is improved, but device complexity increases
Solution Approach 1:
The patent segments the combination formulation into distinct functional components: an inner osmotic pump core containing nifedipine/nisoldipine for sustained release, and an outer coating layer containing angiotensin II antagonist and/or co-diuretic for immediate release. This segmentation allows each component to perform its specific function while maintaining overall system simplicity and manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dosage form ensures rapid release of angiotensin II antagonists and diuretics within 30 minutes and controlled release of nifedipine over 24 hours, reducing side effects and improving blood pressure control, while maintaining stability and bioequivalence to individual formulations.
Implementation Method 1
the core is an osmotic release system
Implementation Method 2
the shell of the osmotic release system consists of cellulose acetate or a mixture of cellulose acetate and polyethylene glycol
Implementation Method 3
the coating contains at least one film-forming polymer suitable for the rapid release of active ingredients, wherein the film-forming polymer is partially hydrolyzed polyvinyl alcohol
Data Source
AI summary
The invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin-II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine are controlled (modified) in the body and the angiotensin-II antagonist and/or the diuretic is quickly released (immediate release (IR)), and to a method for production thereof, to the use thereof as a medicine and to the use thereof for prophylaxis, secondary prophylaxis or treatment of illnesses.